Suven Life Sciences Ltd announces today that the grant of one product patent from Eurasia (020506) and one product patent from Israel (220229) corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2029 and 2030 respectively.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of 14 granted patents from Eurasia and three granted patents from Israel. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally” says Venkat Jasti, chief executive officer, of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.